# Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)

> **NCT06864975** · PHASE4 · RECRUITING · sponsor: **Runhui WU** · enrollment: 110 (estimated)

## Conditions studied

- Hemophilia a with Inhibitor

## Interventions

- **DRUG:** Advate®
- **DRUG:** Advate®
- **DRUG:** Advate®
- **DRUG:** Advate®
- **DRUG:** Advate®

## Key facts

- **NCT ID:** NCT06864975
- **Lead sponsor:** Runhui WU
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2028-03-01
- **Final completion:** 2028-06-21
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06864975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06864975, "Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06864975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*